On August 3, 2026, the biopharmaceutical company Altimmune announced it had begun enrolling patients in PERFORMA, a global phase 3 trial of an investigational medicine called pemvidutide for MASH with moderate to advanced fibrosis. The announcement matters because it moves a distinct mechanism - a balanced glucagon/GLP-1 dual receptor agonist - into the late-stage testing that could eventually support approval.
Pemvidutide is a peptide that activates two receptors at once, in a one-to-one balance. The glucagon side acts directly on the liver, while the GLP-1 side handles the metabolic effects - appetite suppression and weight loss - and the reward pathways relevant to its separate development in alcohol use disorder. That dual design is the point: a medicine that hits the liver directly while also addressing the metabolic dysfunction that drives most MASH.
How the PERFORMA trial is built
PERFORMA is a randomized, double-blind, placebo-controlled study with two parallel cohorts. Cohort 1 will enroll roughly 990 patients and is designed to support the accelerated approval pathway using a biopsy-assessed primary endpoint of MASH resolution and/or fibrosis improvement at 52 weeks. Cohort 2 will enroll about 800 patients whose fibrosis is confirmed by non-invasive tests, adding to the safety dataset. Both cohorts feed the final approval, which will rest on liver-related events at around 60 months.
Two details are worth noting. The dosing uses a simple one- or two-step monthly titration from 1.2 mg up to 1.8 mg or 2.4 mg, which is designed to improve tolerability - important because gastrointestinal side effects are the main challenge in this class. And the trial integrates an FDA-qualified AI tool called AIM-MASH to standardize how biopsy samples are scored, which speaks to how much the field now relies on consistent histology for these endpoints. The 52-week data readout is anticipated in 2029.
The path that led here
Pemvidutide reached phase 3 on the back of the IMPACT phase 2b study, which reported statistically significant MASH resolution rates, improvements in non-invasive measures of fibrosis and liver health, and meaningful weight loss with a generally favorable tolerability profile. The FDA has granted pemvidutide Fast Track designation and Breakthrough Therapy designation for MASH. That is the kind of agency attention reserved for candidates with early signals of meaningful advantage.
The honest caveat is the same one that applies to every phase 3: phase 2 signals do not always survive a larger, longer, placebo-controlled test. The 2029 readout is years away, and the trial is built for the long game - liver-related events at 60 months. For a reader, the right posture is informed patience, not a verdict.
Where the plate still comes first
No matter how promising a pipeline gets, the food guidance does not move. The trial itself is premised on a population where more than 80% of patients are overweight or obese - a reminder that the metabolic foundation is the disease’s core, and that foundation is what the plate addresses every day. The database rates the Recommended column - vegetables, legumes, whole grains, fish, olive oil, fruit - as the pattern that lowers liver fat and insulin resistance without a prescription.
The specific numbers stay useful while the medicine is still years away. Rolled oats sit in Recommended at about 10 grams of fiber per 100 grams. Fatty fish like salmon rate Recommended at roughly 1.3 grams of saturated fat per 100 grams with omega-3s. Lean proteins and legumes anchor the plate during any weight-loss phase. These are the tools a reader has today, and they are the same tools that will complement a medicine like pemvidutide if it reaches the clinic.
How our editorial team read this
Pipeline stories invite hype, so we read this one with a flat tone. Our data editor confirmed the trial design, the cohort sizes, the titration schedule, and the 2029 timing against the company’s own release, and we did not inflate the IMPACT phase 2 results beyond what the company reported - statistically significant resolution rates and non-invasive improvements, not a cure. We kept the phase 2-to-phase 3 risk explicit because it is the single most important thing a reader should carry away from an early pipeline story.
What we did do is keep the reader’s feet on the ground. The medicine is years from a possible approval, and the food pattern is available now. The honest reader-facing line: watch the pipeline with patience, and in the meantime run the pattern - Recommended column, minimal added sugar, regular activity, and a clinician who tracks the liver enzymes and stiffness.
The practical takeaway
For someone with MASH and fibrosis, PERFORMA is a reason for cautious optimism, not an action item. Nothing about it changes the plate or the clinic visit. The database covers the pattern today; the trial will answer its question years from now; the clinician connects both to the individual patient.